Goldman Sachs’s Vivani Medical, Inc. Warrants expiring 03/14/2024 VANIW Stock Holding History

Goldman Sachs’s Portfolio VANIW Stock Details VANIW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-54,247	Closed	-$14K	–	7112
2021 Q4	$14K	Hold	54,247	–	–	﹤0.01%	6397
2021 Q3	$42K	Hold	54,247	–	–	﹤0.01%	6080
2021 Q2	$65K	Buy	54,247 +8,217	+18%	+$11.1K	﹤0.01%	6037
2021 Q1	$73K	Buy	46,030 +19,646	+74%	+$19.3K	﹤0.01%	5896
2020 Q4	$6K	Buy	+26,384	New	+$3K	﹤0.01%	5447

Other funds holding VANIW

SPC

Sigma Planning Corp Ann Arbor, Michigan $3.6B AUM 24.57% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Goldman Sachs's VANIW Position: Q1 2022 in Review

Goldman Sachs sold out of Vivani Medical, Inc. Warrants expiring 03/14/2024 (VANIW) in Q1 2022, closing a stake of 54,247 shares — an estimated $14K sold.

Goldman Sachs first reported a position in VANIW in Q4 2020 and held it in 5 quarters. The position peaked at $73K in Q1 2021. 3 funds tracked by Wall St. Rank hold VANIW as of Q1 2022.

Goldman Sachs reported no remaining Vivani Medical, Inc. Warrants expiring 03/14/2024 position as of Q1 2022 after selling out during the quarter.
Goldman Sachs sold 54,247 Vivani Medical, Inc. Warrants expiring 03/14/2024 shares in Q1 2022, an estimated $14K.
Goldman Sachs first reported a position in Vivani Medical, Inc. Warrants expiring 03/14/2024 in Q4 2020 and held it in 5 quarters.
Goldman Sachs's Vivani Medical, Inc. Warrants expiring 03/14/2024 position peaked at $73K in Q1 2021.
3 funds tracked by Wall St. Rank held Vivani Medical, Inc. Warrants expiring 03/14/2024 as of Q1 2022.

Based on Goldman Sachs's 13F filing for Q1 2022, filed 16 May 2022.